[go: up one dir, main page]

US20130330404A1 - Extended release composition containing tramadol - Google Patents

Extended release composition containing tramadol Download PDF

Info

Publication number
US20130330404A1
US20130330404A1 US13/506,390 US201213506390A US2013330404A1 US 20130330404 A1 US20130330404 A1 US 20130330404A1 US 201213506390 A US201213506390 A US 201213506390A US 2013330404 A1 US2013330404 A1 US 2013330404A1
Authority
US
United States
Prior art keywords
tramadol
composition
hours
plasma concentration
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/506,390
Inventor
Arthur M. Deboeck
Francis Vanderbist
Antonio Sereno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galephar P R Inc Ltd
Original Assignee
Galephar P R Inc Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galephar P R Inc Ltd filed Critical Galephar P R Inc Ltd
Priority to US13/506,390 priority Critical patent/US20130330404A1/en
Publication of US20130330404A1 publication Critical patent/US20130330404A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to a once daily extended release oral Tramadol pharmaceutical preparation which provides effective blood concentration for a period of about 24 hours with reduced peak Tramadol plasma concentrations.
  • the formulation of the present invention provides peak Tramadol plasma concentrations that are less than twice the plasma concentration measured 24 hours after administration, while providing for effective Tramadol plasma concentration about 1 to 2 hours after administration.
  • Tramadol is a centrally acting synthetic analgesic compound that is not derived from natural sources nor is it chemically related to opiates. Although its mode of action is not completely understood, at least two complementary mechanisms appear applicable: Binding to ⁇ -opioid receptors and inhibition of reuptake of nor epinephrine and serotonin. Tramadol opioid activity derives from low affinity binding the parent compound to ⁇ -opioid receptors and higher affinity binding of the M1 metabolite. In animal models. M1 is up to 6 times more potent than Tramadol in producing analgesia and 200 times more potent in ⁇ -opioid binding. The contribution to human analgesia of Tramadol relative to M1 is unknown.
  • Tramadol-induced antinociception is only partially antagonized by the opiate antagonist naloxone in animal test.
  • Tramadol inhibits reuptake of nor-epinephrine and serotonin in-vitro after oral administration of immediate release dosage form the onset of analgesia is evident within 1 hour after administration and reaches a peak in ⁇ 2 to 3 hours. Peak plasma concentrations are reached about 2 hours after administration, which correlates closely with the time to peak pain relief.
  • Tramadol immediate release is rapidly and almost completely absorbed after oral administration.
  • the mean absolute bioavailability of 100 mg oral dose is ⁇ 75%. Administration with food does not significantly affect its rate or extent of absorption; therefore, it can be administered without regard to meals.
  • the mean peak plasma concentration is 308 ⁇ 78 ng/ml and occurs at ⁇ 2 hours after a single 100 mg oral dose in healthy subjects. At this dose the mean peak plasma concentration of the active mono-O-desmethyl metabolite (racemic 1) is 55 ⁇ 20 ng/ml and occurs ⁇ 3 hours post-dose.
  • the separate [+]- and [ ⁇ ]-enantiomers of Tramadol generally follow a parallel time course in plasma after a single 100 mg oral dose.
  • the maximum plasma concentrations of the [ ⁇ ]-enantiomers are some-what lower than those of the [+]-enantiomer (148 ⁇ 33 vs. 168 ⁇ 36 ng/ml, respectively).
  • the [ ⁇ ]-M1 enantiomer (35 ⁇ 10 vs. 26 ⁇ 13 ng/ml, respectively).
  • Steady state is achieved after 2 days of a 100 mg four times daily dosing regimen (maximum plasma concentration was 592 ⁇ 177 ng/ml).
  • the plasma half-life of Tramadol, following single and multiple dosing, was 6 and 7 hours, respectively.
  • the most common adverse reaction is nausea, vertigo, constipation and headaches and is correlated to the patients plasma Tramadol concentrations.
  • Tramadol is used for the management of moderate to moderately severe pain such as pain following surgical procedures (orthopedic, gynecological, cesarean section) and pain following dental surgery (extraction of impacted molars).
  • Tramadol ability to control pain is directly related to its concentration in the patient's plasma stream.
  • the minimum effective therapeutical Tramadol plasma level is around 100 ng/ml. Due to Tramadol plasma elimination short half-live to maintain the minimum effective plasma levels requires generally the oral administration of 50 to 100 mg every 4 to 6 hours of immediate release Pharmaceutical compositions. This administration schedule of the drug makes it difficult for the patient to control pain, specially during night time, since pain will reappear every 4 to 6 hours.
  • U.S. Pat. No. 5,601,842 discloses a tablet containing Tramadol and a matrixing agent with a viscosity between 3,000 and 150,000 mPa in a 2% aqueous solution at 20° C.
  • U.S. Pat. No. 5,811,126 discloses a controlled release pharmaceutical composition containing Tramadol and comprising sodium alginate, C 2 to C 50 , edible hydrocarbon derivative with melting point range from 25° C. to 90° C. and divalent salt to cross link the alginate. In vivo performance from these formulations is not available.
  • U.S. Pat. Nos. 5,639,476 (12h) and 5,580,578 discloses controlled release dosage form containing a substrate containing Tramadol, said substrate being coated with a plasticized aqueous dispersion of ammonio-methacrylate copolymer having low content of quaternary ammonium groups and a permeability enhancing pore former said coating being cured for about 24 to about 60 hours to stabilize said formulation.
  • U.S. Pat. No. 5,955,104 discloses a delayed release Tramadol formulation consisting of pellets in a water soluble capsule or in a tablet compressed from said pellets, each pellet having (a) a substantially inert core; (b) an active ingredient layer containing (i) Tramadol particles in mixture with a binder for adhering said Tramadol particles over said inert core, and optionally (iii) a pharmaceutically acceptable, inner adjuvant; and (c) a delay coating for retarding the release of Tramadol consisting principally of mixtures of Ethylcellulose and shellac.
  • U.S. Pat. Nos. 5,645,858, 5,474,786 and 5,395,626 discloses multilayered controlled release pharmaceutical dosages forms for water soluble drugs comprising a plurality of coated beads and which comprises a core and seven or eight different coatings.
  • U.S. Pat. No. 5,849,240 describes a process for the manufacture of particles by the “melt-pelletization” process.
  • Tramadol is one of the examples but in vivo performances of such formulation is not available.
  • U.S. Pat. No. 5,968,551 (continuation of U.S. Pat. No. 5,273,760) describes sustained release oral analgesic form for once a day administration comprising a unit dose comprising a plurality of pharmaceutical acceptable matrices comprising an analgesically effective amount of Tramadol ad hydrophobic material each of said matrices having a diameter of about 0.1 to 3 mm bioavailability and therapeutical effect for about 24 hours or more after oral administration to a human patient (no control of side effect).
  • U.S. Pat. No. 5,965,163 describes a solid dosage form comprising a plurality of particles including Tramadol in a matrix, the matrix including a mixture of hydrophobic and hydrophilic fusible carries having melting point from 35° C. to 150° C., which are produced by the method of “melt pelletization”.
  • U.S. Pat. No. 5,591,452 discloses a once daily Tramadol preparation constituted of Tramadol incorporate into a controlled release matrix constituted of one or more hydrophilic or hydrophobic polymers which provides a T max of about 3 to about 6 hours.
  • U.S. Pat. No. 5,958,482 describes a sustained release pharmaceutical formulation comprising an extruded blend of Tramadol, and one or more hydrophobic fusible carriers having a melting point from about 30° to about 200° C., providing a sustained-release of said therapeutically active agent for a time period of from about 8 to about 24 hours. With a peak plasma for about 2 to 8 hours.
  • U.S. Pat. No. 5,891,471 discloses Tramadol pharmaceutical particles for once a day administration which provides a time to peak plasma level of Tramadol in about 2 to about 6 hours after administration, produced by a process of “melt-pelletization”.
  • U.S. Pat. Nos. 5,672,360 and 5,478,577 discloses a method of treating pain in humans comprising orally administering of a once a day basis an oral sustained release dosage form of an oploid analgesic which upon single dose and multiple doses administration provides a time to maximum plasma concentration (T max ) of said opioid in about 2 to 10 hours and a maximum plasma concentration (C max ) which is more than twice the plasma level of said opioid at about 24 hours after administration of the dosage form and which, dosage form provides effective treatment of pain for about 24 hours or more after administration to the patient.
  • T max time to maximum plasma concentration
  • C max maximum plasma concentration
  • a pharmaceutical oral dosage formulation of Tramadol a) providing rapidly effective plasma concentration and b) able to maintain such effective plasma concentration for a long period of time while simultaneously avoiding peak Tramadol blood concentrations would be highly desirable to provide an immediate and extended duration of analgesia without low incidence of adverse effects to patients in pain.
  • the Tramadol (or salt) once daily composition of the present invention permit the rapid obtention of Tramadol effective plasma concentration, within one or two hours which are maintained for a period of about 24 hours while providing for peak Tramadol blood concentration which are less than three times the concentration obtained twenty four hours after administration.
  • FIG. 1 illustrates Tramadol and O-desmethyl Tramadol mean blood concentration obtained after single administration to 8 volunteers of one capsule of example 5 (200 mg) data in Table 1 and 2.
  • FIG. 2 illustrates Tramadol and O-desmethyl Tramadol mean blood concentration obtained after multiple, 7 consecutive, once a day administration to 8 volunteers of one capsule of the product of example 5 containing 200 mg of Tramadol (data in Table 3 and 4).
  • the present invention relate to a novel Tramadol pharmaceutical preparations that provide effective Tramadol plasma concentrations one or two hours after administration and which will be maintained for 24 hours while simultaneously avoiding excessive Tramadol plasma concentrations which are the origin of the unwanted side effects.
  • the present invention is related to the discovery, contrary to the teaching of U.S. Pat. Nos. 5,672,360 and 5,478,577 that in order to control pain for about 24 hours, it is necessary that the peak of opioid analgesics concentration (C max ) is more than twice the concentration obtained 24 hours after administration.
  • C max peak of opioid analgesics concentration
  • the present invention is related to the discovery that in order to provide for Tramadol peak plasma concentrations that are less than three times the plasma concentration obtained 24 hours after administration it is necessary that the pharmaceutical composition has an in vitro release profile that is not of the first order but rather multiphasic.
  • the present invention relates to a once daily oral pharmaceutical composition
  • a once daily oral pharmaceutical composition comprising a unit dose with at least two Tramadol containing portions who release the Tramadol at different rates.
  • the unit dose may be per example a hard gelatine and/or hydroxypropylmethylcellulose capsule for oral administration.
  • the present invention relate to a unit dose that contains a Tramadol portion who liberate slowly the Tramadol and a Tramadol containing portions that liberates the Tramadol in a faster manner.
  • the unit dose may be a hard capsule and/or a tablet.
  • the unit dose comprises a hard gelatine and/or hydroxypropylcellulose capsule containing slow release beads and a fast releasing Tramadol tablet.
  • any pharmaceutically acceptable salt of Tramadol may be used.
  • the hydrochloride salt of Tramadol may be used.
  • the unit dose comprises hard gelatine and/or hydroxypropylmethylcellulose capsule containing a slow release tablet and fast releasing beads.
  • the unit dose comprises hard gelatine and/or hydroxypropylmethylcellulose capsule containing slow release beads covered by layers of fast release Tramadol.
  • Bead which are spheroids containing Tramadol or any of its salts may be produced by any conventional known method such as layering the Tramadol in solution with water over a neutral core, or layering over a core the Tramadol in mixture with other pharmaceutical acceptable excipients such as a binders, polymers.
  • the preferred method for the manufacture of beads in the present invention is the method of extrusion-spheronization.
  • This method comprises mixing the Tramadol or its salts with a spheronizing agent such as microcrystalline cellulose and optionally other pharmaceutical excipients with water.
  • a spheronizing agent such as microcrystalline cellulose and optionally other pharmaceutical excipients with water.
  • the blend obtained is thereafter extruded trough an extruder and the extrudate is thereafter rounded with the help of a spheronizer.
  • beads are produced without any binder and comprises a mixture of Tramadol hydrochloride, microcrystalline cellulose and sucrose stearate.
  • Sustained release bead are obtained by coating beads, previously manufactured, with a porous membrane from which the Tramadol is liberated slowly.
  • the microporous membrane comprises mixtures of water—soluble and/or water dispersible polymers and/or copolymers and may also include pharmaceutically acceptable adjuvants such as plastifying agents, pigments, fillers, wetting agents, lubricants and anti-foam agents.
  • water—soluble and/or dispersible film forming polymers or copolymers constituting the microporous membrane may be mentioned particularly polyacrylates and polymethacrylates of the Eudragit type, such as Eudragit E30D, L30D, RS30 D NE30D of Röhm Phama (USA), ethylcelluoses, such as Ethocels of DOW, USA and such as AquaCoat of FMC, USA, Hydroxypropyl cellulose and hydroxypropylmethylcellulose and their derivatives.
  • Eudragit type such as Eudragit E30D, L30D, RS30 D NE30D of Röhm Phama (USA)
  • ethylcelluoses such as Ethocels of DOW, USA and such as AquaCoat of FMC, USA, Hydroxypropyl cellulose and hydroxypropylmethylcellulose and their derivatives.
  • the polymers or copolymers may be associated into the microporous membrane with at least one adjutant as exemplified by the following: Plastifying agents, such as triacetin, dibutylphthalate, dibutylsebacate, citric acid esters, polyethyleneglycols, polypropyleneglycols and polyvinylpyrrolidone; Pigments such as iron oxides and titanium oxide; fillers, such as lactose and sucrose; Wetting agents, such as surfactive agents of the Span and Tween types, namely partial esters of fatty acids (lauric, palmitic, stearic and oleic acids) and anhydrides of hexitols derived from sorbitol possibly containing polyoxyethylenic chains, preferably surfactive agents of the Tween type, namely Tween 80, as well as polyethyleneglycols; lubricants, such as magnesium stearate and talc; antifoaming agents, such as
  • the microporous membrane contains preferably, talc and/or magnesium stearate as a lubricant, polyvinylpyrrolidone as a plastifying agent, titanium dioxide as a pigment, Tween 80 as an emulsifier, and silicone oil as an antifoaming agent.
  • the thickness of the microporous membrane is expressed by the percentage of the dry coating applied onto the uncoated beads.
  • the weight of the microporous membrane may be 2 to 55%, preferably, 10 to 40%, of the weight of said microgranules. These beads may contain the Tramadol or its salt in an amount of 20 to 95% by weight, preferably 30 to 85% by weight.
  • the microporous membrane may contain 5 to 95% and, preferably, 30 to 50% of polymers, polymer mixture or copolymers.
  • microporous membrane for use in the present invention may be applied by coating in equipment such as fluid bed coaters, pan coaters or any suitable coating equipment.
  • the tablet of the present invention which will be included in the unit dose may be of the fast and/or as sustained release type.
  • fast release tablets are used.
  • the tablets useful for the present invention shall be of such size that it may be incorporated into the capsule. Tablets having a diameter comprise between 3 and 5 mm are suitable for the present invention.
  • the amount of Tramadol or its salts included into the tablet shall be such that the tablet peak plasma concentration is less than the peak concentration of the beads included in the unit dose.
  • the unit dose Tramadol ratio between the fast release and the sustained release beads is comprised between 1 and 50%, preferably between 5% and 40% and more preferably between 10 and 30%.
  • the fast release tablets useful for the present invention comprises Tramadol or its salt in mixture with pharmaceutical tabletting agents.
  • the tablets may be produced using conventional tabletting technics.
  • Sustained release tablets useful for the present invention comprises Tramadol or its salts in combination with retarding agent such as cellulose derivatives, acrylic polymers.
  • the sustained release beads coated with the microporous membrane may be covered by layers of a fast release Tramadol.
  • Tramadol or its salts in solution and/or suspension in a solvent is applied onto the coated beads.
  • Adjuvants such as plastifying agents, pigments, fillers, wetting agents lubricants and antifoam agents may also been included.
  • the overcoated Tramadol containing layer may also contain polymer and a copolymers or mixtures thereof to control the release of the fast releasing Tramadol layer.
  • the sustained release coating was applied onto the pre coated beads.
  • the coated beads were placed onto trays in a drying oven for about 16 hours at 50° C. Upon cooling the coated beads were stored in containers for further use.
  • Hard gelatine capsule size #0 where filled with 386.7 mg of beads from Example 2 and one tablet from Example 3 to provide a composition containing 200 mg of Tramadol Hcl per capsule.
  • the dissolution profile is not of the first order type but of the biphasic type.
  • a single dose of 200 mg of Tramadol Hcl from Example 5 was administered to 8 healthy volunteers and blood concentrations were measured up to 36 hours after administration.
  • Example 2 30 kg of beads from Example 1 were coated first with 5.5 kg of the precoating suspension of Example 2 followed by 36 kg of the sustained release coating of Example 2.
  • Tablets containing 30 mg Tramadol were prepared as per method described in Example 3—using a 160 L planetary blend. The tablets weight was 75 mg.
  • Hard gelatin capsules Size #0 were filled with one tablet of Example 7 and 341 mg of beads from Example 6 treated with 0.5% of Talc.
  • Hard gelatin capsules Size #00 were filled with one tablet of Example 7 and 568 mg of beads from Example 6 treated with 0.5% of Talc.
  • Single Tramadol ER capsules containing 200 mg and 300 mg were administered in cross over to twenty healthy subjects without food. Blood was monitor and plasma analyzed for Tramadol content up to 72 hours.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

An oral tramadol pharmaceutical composition for once daily administration, containing an effective amount of tramadol or a pharmaceutically-acceptable salt thereof, providing in vivo, a time of tramadol peak plasma concentration (Tmax) greater than 10 hours and a peak tramadol plasma concentration (Cmax) which is less than three times a plasma concentration obtained 24 hours after administration (C24h) of a single dose of the composition.

Description

    BACKGROUND OF THE INVENTION
  • The present invention relates to a once daily extended release oral Tramadol pharmaceutical preparation which provides effective blood concentration for a period of about 24 hours with reduced peak Tramadol plasma concentrations. The formulation of the present invention provides peak Tramadol plasma concentrations that are less than twice the plasma concentration measured 24 hours after administration, while providing for effective Tramadol plasma concentration about 1 to 2 hours after administration.
  • Tramadol is a centrally acting synthetic analgesic compound that is not derived from natural sources nor is it chemically related to opiates. Although its mode of action is not completely understood, at least two complementary mechanisms appear applicable: Binding to μ-opioid receptors and inhibition of reuptake of nor epinephrine and serotonin. Tramadol opioid activity derives from low affinity binding the parent compound to μ-opioid receptors and higher affinity binding of the M1 metabolite. In animal models. M1 is up to 6 times more potent than Tramadol in producing analgesia and 200 times more potent in μ-opioid binding. The contribution to human analgesia of Tramadol relative to M1 is unknown.
  • Tramadol-induced antinociception is only partially antagonized by the opiate antagonist naloxone in animal test. In addition, Tramadol inhibits reuptake of nor-epinephrine and serotonin in-vitro after oral administration of immediate release dosage form the onset of analgesia is evident within 1 hour after administration and reaches a peak in ≈2 to 3 hours. Peak plasma concentrations are reached about 2 hours after administration, which correlates closely with the time to peak pain relief.
  • Tramadol immediate release is rapidly and almost completely absorbed after oral administration. The mean absolute bioavailability of 100 mg oral dose is ≈75%. Administration with food does not significantly affect its rate or extent of absorption; therefore, it can be administered without regard to meals. The mean peak plasma concentration is 308±78 ng/ml and occurs at ≈2 hours after a single 100 mg oral dose in healthy subjects. At this dose the mean peak plasma concentration of the active mono-O-desmethyl metabolite (racemic 1) is 55±20 ng/ml and occurs ≈3 hours post-dose. The separate [+]- and [−]-enantiomers of Tramadol generally follow a parallel time course in plasma after a single 100 mg oral dose. Following a 100 mg dose, the maximum plasma concentrations of the [−]-enantiomers are some-what lower than those of the [+]-enantiomer (148±33 vs. 168±36 ng/ml, respectively). The [−]-M1 enantiomer (35±10 vs. 26±13 ng/ml, respectively). Steady state is achieved after 2 days of a 100 mg four times daily dosing regimen (maximum plasma concentration was 592±177 ng/ml). The plasma half-life of Tramadol, following single and multiple dosing, was 6 and 7 hours, respectively. The most common adverse reaction is nausea, vertigo, constipation and headaches and is correlated to the patients plasma Tramadol concentrations.
  • Tramadol is used for the management of moderate to moderately severe pain such as pain following surgical procedures (orthopedic, gynecological, cesarean section) and pain following dental surgery (extraction of impacted molars).
  • Tramadol ability to control pain is directly related to its concentration in the patient's plasma stream. The minimum effective therapeutical Tramadol plasma level is around 100 ng/ml. Due to Tramadol plasma elimination short half-live to maintain the minimum effective plasma levels requires generally the oral administration of 50 to 100 mg every 4 to 6 hours of immediate release Pharmaceutical compositions. This administration schedule of the drug makes it difficult for the patient to control pain, specially during night time, since pain will reappear every 4 to 6 hours.
  • On the other hand, if patient in an attempt to control pain for a longer period of time should take higher doses of immediate release Tramadol than peak plasma levels will increase dramatically and very serious side effects due to high blood levels will appear immediately.
  • Another difficulty encountered by the man skilled in the art for the production of a once daily Tramadol formulation arises from Tramadol extremely high solubility in water and body fluids. The prior art teaching related to Tramadol compositions that may be useful for once daily administration are basically related to maintain effective therapeutically plasma concentrations between administration. Since It is known that the therapeutically effective Tramadol plasma levels are close to the unwanted adverse reaction plasma levels, once a day Tramadol compositions to be useful to treat effectively patients in need must not only provide for minimum effective therapeutic plasma levels but also must provide for the control of toxic levels. Any once a day Tramadol formulation which should not comply with both requirements would be useless.
  • U.S. Pat. No. 5,601,842 discloses a tablet containing Tramadol and a matrixing agent with a viscosity between 3,000 and 150,000 mPa in a 2% aqueous solution at 20° C. U.S. Pat. No. 5,811,126 discloses a controlled release pharmaceutical composition containing Tramadol and comprising sodium alginate, C2 to C50, edible hydrocarbon derivative with melting point range from 25° C. to 90° C. and divalent salt to cross link the alginate. In vivo performance from these formulations is not available.
  • U.S. Pat. Nos. 5,639,476 (12h) and 5,580,578 discloses controlled release dosage form containing a substrate containing Tramadol, said substrate being coated with a plasticized aqueous dispersion of ammonio-methacrylate copolymer having low content of quaternary ammonium groups and a permeability enhancing pore former said coating being cured for about 24 to about 60 hours to stabilize said formulation.
  • U.S. Pat. No. 5,955,104 discloses a delayed release Tramadol formulation consisting of pellets in a water soluble capsule or in a tablet compressed from said pellets, each pellet having (a) a substantially inert core; (b) an active ingredient layer containing (i) Tramadol particles in mixture with a binder for adhering said Tramadol particles over said inert core, and optionally (iii) a pharmaceutically acceptable, inner adjuvant; and (c) a delay coating for retarding the release of Tramadol consisting principally of mixtures of Ethylcellulose and shellac.
  • U.S. Pat. Nos. 5,645,858, 5,474,786 and 5,395,626 discloses multilayered controlled release pharmaceutical dosages forms for water soluble drugs comprising a plurality of coated beads and which comprises a core and seven or eight different coatings.
  • U.S. Pat. No. 5,849,240 describes a process for the manufacture of particles by the “melt-pelletization” process. Tramadol is one of the examples but in vivo performances of such formulation is not available.
  • U.S. Pat. No. 5,968,551 (continuation of U.S. Pat. No. 5,273,760) describes sustained release oral analgesic form for once a day administration comprising a unit dose comprising a plurality of pharmaceutical acceptable matrices comprising an analgesically effective amount of Tramadol ad hydrophobic material each of said matrices having a diameter of about 0.1 to 3 mm bioavailability and therapeutical effect for about 24 hours or more after oral administration to a human patient (no control of side effect). It also discloses (claim 33) a method of treating patients for moderate to severe pain with a once, daily oral administration of a unit dose consisting of a plurality of inert pharmaceutical acceptable beads control with an analgesically effective amount of an opioid analgesically effective amount of analgesic said beads having a diameter of 0.1 to 3 mm and having effective blood levels for about 24 hours (against side effects) with a peak of said opioid in vivo for about 3 to about 10 hours after administration.
  • U.S. Pat. No. 5,965,163 describes a solid dosage form comprising a plurality of particles including Tramadol in a matrix, the matrix including a mixture of hydrophobic and hydrophilic fusible carries having melting point from 35° C. to 150° C., which are produced by the method of “melt pelletization”.
  • U.S. Pat. No. 5,591,452 discloses a once daily Tramadol preparation constituted of Tramadol incorporate into a controlled release matrix constituted of one or more hydrophilic or hydrophobic polymers which provides a Tmax of about 3 to about 6 hours.
  • U.S. Pat. No. 5,958,482 describes a sustained release pharmaceutical formulation comprising an extruded blend of Tramadol, and one or more hydrophobic fusible carriers having a melting point from about 30° to about 200° C., providing a sustained-release of said therapeutically active agent for a time period of from about 8 to about 24 hours. With a peak plasma for about 2 to 8 hours.
  • U.S. Pat. No. 5,891,471 discloses Tramadol pharmaceutical particles for once a day administration which provides a time to peak plasma level of Tramadol in about 2 to about 6 hours after administration, produced by a process of “melt-pelletization”.
  • U.S. Pat. Nos. 5,672,360 and 5,478,577 discloses a method of treating pain in humans comprising orally administering of a once a day basis an oral sustained release dosage form of an oploid analgesic which upon single dose and multiple doses administration provides a time to maximum plasma concentration (Tmax) of said opioid in about 2 to 10 hours and a maximum plasma concentration (Cmax) which is more than twice the plasma level of said opioid at about 24 hours after administration of the dosage form and which, dosage form provides effective treatment of pain for about 24 hours or more after administration to the patient.
  • An orally administrable Tramadol formulation for once a day administration, which would provide effective Tramadol plasma concentrations without Tramadol plasma peaks would be highly desirable.
  • A pharmaceutical oral dosage formulation of Tramadol a) providing rapidly effective plasma concentration and b) able to maintain such effective plasma concentration for a long period of time while simultaneously avoiding peak Tramadol blood concentrations would be highly desirable to provide an immediate and extended duration of analgesia without low incidence of adverse effects to patients in pain.
  • The Tramadol (or salt) once daily composition of the present invention permit the rapid obtention of Tramadol effective plasma concentration, within one or two hours which are maintained for a period of about 24 hours while providing for peak Tramadol blood concentration which are less than three times the concentration obtained twenty four hours after administration.
    • OBJECT AND SUMMARY OF THE INVENTION
  • It is an object of the present invention to provide a once a day oral pharmaceutical preparation of Tramadol or its pharmaceutical acceptable salts.
  • It is another object of the present invention to provide a once a day Tramadol pharmaceutical preparation which is able to provide effective Tramadol plasma concentration for a period of about 24 hours.
  • It is another object of the present invention to provide a once daily oral Tramadol preparation which provides effective plasma concentrations within about 1 to 2 hours after single administration of an effective amount of Tramadol for said formulation.
  • It is another object of the present invention to provide a once a day Tramadol pharmaceutical preparation which effectively reduces the excessive Tramadol plasma concentration.
  • It is another object of the present invention to provide a Tramadol once a day oral pharmaceutical preparation which after single dose administration to humans provides Tramadol peak plasma concentration (Cmax) less than three times the plasma concentration obtained 24 hours (C24h) after said formulation.
  • It is another object of the present invention to provide a Tramadol once a day oral pharmaceutical preparation which after multiple doses administration to humans provides Tramadol peak plasma concentration (Cmax), which are less than three times the plasma concentration obtained 24 hours (C24h) after said multiple administrations.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 illustrates Tramadol and O-desmethyl Tramadol mean blood concentration obtained after single administration to 8 volunteers of one capsule of example 5 (200 mg) data in Table 1 and 2.
  • FIG. 2 illustrates Tramadol and O-desmethyl Tramadol mean blood concentration obtained after multiple, 7 consecutive, once a day administration to 8 volunteers of one capsule of the product of example 5 containing 200 mg of Tramadol (data in Table 3 and 4).
    •
  • It is another object of the present invention to provide a Tramadol once a day oral pharmaceutical preparation which after single and/or multiple doses administration to humans provides Tramadol peak concentrations not less than 10 hours (Tmax) after said administration.
  • It is another object of the present invention to provide a once daily oral Tramadol pharmaceutical preparation from which the Tramadol rapid rise maximum plasma concentration is lower that the peak concentration of the formulation.
  • It is another object of the present invention to provide a once a day Tramadol pharmaceutical-preparation which is able to control effectively pain during a period of about 24 hours.
  • It is another object of the present invention to provide a once a day Tramadol preparation which reduces pain within 1 to 2 hours after single administration of an effective amount of Tramadol.
  • It is another object of the present invention to provide a once daily oral Tramadol pharmaceutical preparation which effectively reduces the unwanted Tramadol side effects due to excessive Tramadol plasma concentration.
  • It is another object of the present invention to provide a once daily oral Tramadol pharmaceutical preparation which comprise controlled release beads and a tablet into a hard gelatine and/or hydroxypropylmethycellulose capsule.
  • It is another object of the present invention to provide a once daily oral Tramadol preparation from which the plasma Tramadol concentration are not affected when the formulation is taken with or without food.
  • It is another object of the present invention to provide a tablet containing Tramadol controlled release beads and a fast release portion of Tramadol constituted by granules, beads or powder which releases the Tramadol in such a manner that the fast releasing Tramadol portion peak plasma concentration is less than the peak concentration obtained from the Tramadol released from the coated beads.
  • The present invention relate to a novel Tramadol pharmaceutical preparations that provide effective Tramadol plasma concentrations one or two hours after administration and which will be maintained for 24 hours while simultaneously avoiding excessive Tramadol plasma concentrations which are the origin of the unwanted side effects.
  • More particularly the present invention is related to the discovery, contrary to the teaching of U.S. Pat. Nos. 5,672,360 and 5,478,577 that in order to control pain for about 24 hours, it is necessary that the peak of opioid analgesics concentration (Cmax) is more than twice the concentration obtained 24 hours after administration. In other words, what is disclosed in these patents is the need for large fluctuations of opioid analgesic blood concentrations between successive administration.
  • More particularly the present invention is related to the discovery that in order to provide for Tramadol peak plasma concentrations that are less than three times the plasma concentration obtained 24 hours after administration it is necessary that the pharmaceutical composition has an in vitro release profile that is not of the first order but rather multiphasic.
  • More particularly, the present invention relates to a once daily oral pharmaceutical composition comprising a unit dose with at least two Tramadol containing portions who release the Tramadol at different rates. The unit dose may be per example a hard gelatine and/or hydroxypropylmethylcellulose capsule for oral administration.
  • More particularly, the present invention relate to a unit dose that contains a Tramadol portion who liberate slowly the Tramadol and a Tramadol containing portions that liberates the Tramadol in a faster manner. The unit dose may be a hard capsule and/or a tablet.
  • In certain preferred embodiments the unit dose comprises a hard gelatine and/or hydroxypropylcellulose capsule containing slow release beads and a fast releasing Tramadol tablet.
  • In accordance with the present invention any pharmaceutically acceptable salt of Tramadol may be used. In the preferred embodiment the hydrochloride salt of Tramadol may be used.
  • In another preferred embodiment the unit dose comprises hard gelatine and/or hydroxypropylmethylcellulose capsule containing a slow release tablet and fast releasing beads.
  • In another preferred embodiment, the unit dose comprises hard gelatine and/or hydroxypropylmethylcellulose capsule containing slow release beads covered by layers of fast release Tramadol.
  • Bead which are spheroids containing Tramadol or any of its salts may be produced by any conventional known method such as layering the Tramadol in solution with water over a neutral core, or layering over a core the Tramadol in mixture with other pharmaceutical acceptable excipients such as a binders, polymers.
  • The preferred method for the manufacture of beads in the present invention is the method of extrusion-spheronization. This method comprises mixing the Tramadol or its salts with a spheronizing agent such as microcrystalline cellulose and optionally other pharmaceutical excipients with water. The blend obtained is thereafter extruded trough an extruder and the extrudate is thereafter rounded with the help of a spheronizer.
  • In a preferred embodiment beads are produced without any binder and comprises a mixture of Tramadol hydrochloride, microcrystalline cellulose and sucrose stearate.
  • Sustained release bead, are obtained by coating beads, previously manufactured, with a porous membrane from which the Tramadol is liberated slowly. The microporous membrane comprises mixtures of water—soluble and/or water dispersible polymers and/or copolymers and may also include pharmaceutically acceptable adjuvants such as plastifying agents, pigments, fillers, wetting agents, lubricants and anti-foam agents.
  • Among the water—soluble and/or dispersible film forming polymers or copolymers constituting the microporous membrane, may be mentioned particularly polyacrylates and polymethacrylates of the Eudragit type, such as Eudragit E30D, L30D, RS30 D NE30D of Röhm Phama (USA), ethylcelluoses, such as Ethocels of DOW, USA and such as AquaCoat of FMC, USA, Hydroxypropyl cellulose and hydroxypropylmethylcellulose and their derivatives.
  • The polymers or copolymers may be associated into the microporous membrane with at least one adjutant as exemplified by the following: Plastifying agents, such as triacetin, dibutylphthalate, dibutylsebacate, citric acid esters, polyethyleneglycols, polypropyleneglycols and polyvinylpyrrolidone; Pigments such as iron oxides and titanium oxide; fillers, such as lactose and sucrose; Wetting agents, such as surfactive agents of the Span and Tween types, namely partial esters of fatty acids (lauric, palmitic, stearic and oleic acids) and anhydrides of hexitols derived from sorbitol possibly containing polyoxyethylenic chains, preferably surfactive agents of the Tween type, namely Tween 80, as well as polyethyleneglycols; lubricants, such as magnesium stearate and talc; antifoaming agents, such as silicone oil.
  • In addition to the polymer or copolymer, the microporous membrane contains preferably, talc and/or magnesium stearate as a lubricant, polyvinylpyrrolidone as a plastifying agent, titanium dioxide as a pigment, Tween 80 as an emulsifier, and silicone oil as an antifoaming agent.
  • Generally, the thickness of the microporous membrane is expressed by the percentage of the dry coating applied onto the uncoated beads.
  • The weight of the microporous membrane may be 2 to 55%, preferably, 10 to 40%, of the weight of said microgranules. These beads may contain the Tramadol or its salt in an amount of 20 to 95% by weight, preferably 30 to 85% by weight. The microporous membrane may contain 5 to 95% and, preferably, 30 to 50% of polymers, polymer mixture or copolymers.
  • The microporous membrane for use in the present invention may be applied by coating in equipment such as fluid bed coaters, pan coaters or any suitable coating equipment.
  • The tablet of the present invention which will be included in the unit dose may be of the fast and/or as sustained release type. In the preferred embodiment fast release tablets are used. The tablets useful for the present invention shall be of such size that it may be incorporated into the capsule. Tablets having a diameter comprise between 3 and 5 mm are suitable for the present invention. The amount of Tramadol or its salts included into the tablet shall be such that the tablet peak plasma concentration is less than the peak concentration of the beads included in the unit dose. The unit dose Tramadol ratio between the fast release and the sustained release beads is comprised between 1 and 50%, preferably between 5% and 40% and more preferably between 10 and 30%.
  • The fast release tablets useful for the present invention comprises Tramadol or its salt in mixture with pharmaceutical tabletting agents. The tablets may be produced using conventional tabletting technics.
  • Sustained release tablets useful for the present invention comprises Tramadol or its salts in combination with retarding agent such as cellulose derivatives, acrylic polymers.
  • In another embodiment for use in the present invention the sustained release beads coated with the microporous membrane may be covered by layers of a fast release Tramadol. For that purpose, Tramadol or its salts in solution and/or suspension in a solvent is applied onto the coated beads. Adjuvants such as plastifying agents, pigments, fillers, wetting agents lubricants and antifoam agents may also been included. The overcoated Tramadol containing layer may also contain polymer and a copolymers or mixtures thereof to control the release of the fast releasing Tramadol layer.
  • The following examples illustrate various aspects of the present invention. They are not meant to be constituted to limit the claims in any matter whatsoever.
    • EXAMPLE 1 Uncoated Beads
  • Tramadol Hcl 31.8 kg
    Microcrystalline Cellulose (Avicel pH101) 21.0 kg
    Sucrose Stearate (Crosdeta F160) 2.17 kg
    Purified Water 7.24 kg
  • In a planetary mixer collette of 160 liter capacity introduce the Tramadol Hcl, microcrystalline cellulose and the sucrose stearate, blend at speed 2 for about 15 min. Slowly add the purified water and continue mixing for an additional 15 minutes at speed 2 after all water is added. Extrude the blend through a Fuji Paudal extruder equipped with a 1 mm screen. Spheronize the extrudate during about 2 minutes and dry the beads in an oven at 50° C. for about 12 hours. The dried beads are screened though sieves of 1.4 and 0.7 mm. The yields of uncoated beads comprised between 0.7 and 1.4 mm was 44.0 kg (81%).
    • EXAMPLE 2 Coated Beads
  • 2a. Pre Coating
  •
    Hydroxypropylmethylcelllose 1.35 kg
    Talc 5.40 kg
    Purified Water 18.0 kg
      • 45 kg of sieved beads from Example 1 were placed in an fluidized bed coater (Aeromatic). The beads were pre coated with 8.25 kg of the coating suspension.
        2b. Sustained Release Coating
  • Polyacrylate (30%) Eudragit NE30D 36.7 kg
    Hydroxypropylmethylcelllose 1.08 kg
    Talc 1.08 kg
    Polysorbate
    80 0.216 kg 
    Simethicone 0.540 kg 
    Magnesium Stearate 0.216 kg 
    Purified Water 18.0 kg
  • Immediately after the pre coating, 47.8 kg of the sustained release coating was applied onto the pre coated beads. Upon completion of the coating, the coated beads were placed onto trays in a drying oven for about 16 hours at 50° C. Upon cooling the coated beads were stored in containers for further use.
    • EXAMPLE 3 Tramadol Fast Release Tablet—30 mg
  • Tramadol Hcl  3.00 kg
    Lactose  2.63 kg
    Avicel pH102  1.13 kg
    Povidone 0.150 kg
    Starch 0.525 kg
    Magnesium Stearate 0.075 kg
  • Introduce a collette planetary mixer with a 20 liter bowl, all ingredients, except the magnesium stearate, are blend for 15 minutes at speed 2. Add the magnesium stearate and blend for about 1 minute at speed 1. The blend is compressed using dip cup punches of 5 mm diameter to produce 94,000 tablets of 75 mg containing 30 mg of Tramadol Hcl per tablet. The tablets at Example 3 were tested for release of Tramadol using USP Apparatus 1 (Paddles) in 900 mL of a buffer at pH 6.9 at 37° C. and at 50 rotations per minute.
  • Time [h] Tramadol Hcl Dissolved [%]
    0.25 74.5
    0.50 98.6
    0.75 101.8
    • EXAMPLE 4 Fast Release Tablet—15 mg
  • Tramadol Hcl 1.50 kg
    Manitol 3.00 kg
    Povidone XL 1.73 kg
    Povidone 0.20 kg
    Corn Starch 1.00 kg
    Magnesium Stearate 0.075 kg 
  • Following the same manufacturing procedure as in Example 4 to produce the blend, 92,000 tablets weighing 75 mg and containing 15 mg of Tramadol Hcl per tablet where produced.
    • EXAMPLE 5 Tramadol Unit Dose
  • Hard gelatine capsule size #0 where filled with 386.7 mg of beads from Example 2 and one tablet from Example 3 to provide a composition containing 200 mg of Tramadol Hcl per capsule.
  • A dissolution test was performed on this composition using USP Apparatus 1 (paddle) at 100 revolution per minute in 900 mL of water at 37° C.
  • Tramadol percent
    Time [hours] dissolved [%]
    1 18
    2 20
    4 24
    6 32
    8 56
    12 67
    16 82
    22 92
  • As may be seen the dissolution profile is not of the first order type but of the biphasic type.
    • Single Dose Administration
  • A single dose of 200 mg of Tramadol Hcl from Example 5 was administered to 8 healthy volunteers and blood concentrations were measured up to 36 hours after administration.
  • Tramadol Hcl and its metabolite, 0-Desmethyl Tramadol, blood concentrations were measured by LC/MS method. The results are summarized in Tables 1 and 2.
    • Multiple Dose Study
  • 200 mg of the composition of example 5 was given once daily during seven days to 8 healthy volunteers. On day 7 the blood concentration were measured during a period of about 35 hours. Tramadol and its metabolite o-demethyl Tramadol blood concentrations were determined using LC/MS analytical method. The results are in Tables 3 and 4.
  • TABLE 1
    Tramadol plasma levels [mg/ml] obtained from 8 healthy volunteers
    after single administration of Hcl from Example 5 (200 mg).
    Subject 0 h 0.5 0.75 1 1.5 2 4 6 8 10
    1 0 1.068 57.47 61.168 72.609 69.002 45.398 57.97 81.206 84.703
    2 0 0.734 26.894 79.184 104.18 100.95 100.42 163.46 234.15 304.35
    3 0 0.805 42.483 84.899 87.138 92.105 87.27 108.6 127.35 171.3
    4 0 1.135 24.201 134.42 111.62 116.53 78.643 75.297 96.719 134.16
    5 0 0.384 10.726 48.862 100.12 74.449 84.476 100.88 101.3 152.23
    6 0 2.123 3.873 16.958 81.877 67.261 72.954 74.083 78.184 102.07
    7 0 0.09 0.969 19.501 71.931 101.62 124.62 148.51 148.23 197.66
    8 0 10.165 23.992 56.001 104.14 103.35 120.33 126.33 135.05 167
    MEAN 0 2.1 23.8 62.8 91.7 90.7 89.1 106.9 122.8 161.7
    SD 0 3.3286 19.228 36.134 15.356 15.273 25.98 37.456 53.644 71.302
    Subject 12 14 24 36 AUC Cmax Tmax Cmax/C24
    1 109.06 99.172 72.374 25.313 2378.8 109.06 12 1.51
    2 327.05 346.38 201.32 75.774 722.13 348.38 14 1.72
    3 236.23 197.5 169.47 96.063 5288.5 235.23 12 1.38
    4 145.45 138.37 88.483 42.285 3372.7 145.45 12 1.64
    5 144.74 159.64 140.87 67.89 4182.7 159.64 14 1.13
    6 92.148 100.05 70.298 36.974 2587.4 102.07 10 1.45
    7 240.27 280.23 201.99 118.39 6503.5 280.23 14 1.39
    8 196.78 180.56 168.7 62.092 4994.2 186.78 12 1.11
    MEAN 185.2 187.7 139.2 64.3 4563.8 195.73 12.5 1.42
    SD 78.771 86.709 55.257 31.311 1786.9 85.917 1.4142 0.217
  • TABLE 2
    O-demethyl Tramadol plasma levels [mg/ml]obtained from 8 healthy
    volunteers after single administration of 200 mg of Tramadol from Example 5.
    subjects 0 0.5 0.75 1 1.5 2 4 6 8 10 12 14 24 36 AUC Cmax Tmax Cmax/C24
    1 0 0.1 22.3 27.3 33.8 30.4 25.8 26.8 31.1 44.2 43.1 46.8 44.1 19.6 1290.8 45.8 14 1.04
    2 0 0.0 1.8 2.1 5.3 5.7 5.7 8.1 12.1 16.4 13.0 19.5 16.1 6.8 480.57 19.6 14 1.21
    3 0 0.0 4.3 7.4 9.6 11.7 11.1 14.4 18.1 27.9 34.2 28.7 23.9 17.9 777.5 34.2 12 1.43
    4 0 0.0 4.5 22.7 33.5 29.6 25.7 23.6 27.5 41.6 38.0 38.8 36.6 22.1 1121.1 41.6 10 1.17
    5 0 0.0 0.9 5.0 8.8 8.1 9.4 12.5 12.7 21.3 21.9 20.8 28.2 13.1 685.55 28.2 24 1.00
    6 0 2.2 0.4 6.4 21.5 24.9 38.2 26.7 25.7 31.3 30.9 25.6 37.7 17.6 1022.6 37.7 24 1.00
    7 0 0.0 0.0 1.5 8.3 5.3 7.0 9.5 12.1 16.5 18.5 23.8 23.7 18.0 652.47 23.8 14 1.00
    8 0 3.0 6.8 11.3 16.8 19.2 22.8 33.4 35.1 69.0 43.8 42.5 53.4 25.1 1479.6 69.0 10 1.29
    MEAN 0 0.7 5.0 10.5 16.8 18.8 18.0 19.4 24.4 33.8 31.0 30.4 32.8 17.4 936.3 37.6 15.3 1.14
    SD 0 1.20 7.32 9.56 11.65 10.55 11.15 9.38 14.56 17.48 10.46 10.04 12.23 5.85 350.02 15.5 5.7 0.160
  • TABLE 3
    tramadol levels multiple doses
    tramadol plasme concentrations [mg/ml] obtatined after 7 consecutive
    administrations of 200 mg of tramadol HCl from Example 5 to 8 healthy volunteers
    time [hours] after the seventh administration
    subject −24 0 1 1.5 2 4 6 8 10
    1 162.2 187.9 230.5 139.1 271.7 210 209.0 285.5 340.6
    2 128.8 99.5 165.7 172.3 158.1 128 103.4 117.9 161.7
    3 87.4 84.1 104.9 168.8 162.8 181 157.0 180.9 200.2
    4 49.9 82.8 170.4 130.2 135.7 114 110.4 103.6 132.0
    5 104.1 125.9 195.1 191.5 179.0 204 242.4 289.0 358.4
    6 183.2 135.0 207.7 199.5 185.3 150 189.6 183.1 176.4
    7 187.7 193.6 238.4 244.4 224.0 178 198.0 227.9 259.8
    8 81.7 103.1 140.6 150.8 155.3 125 138.9 131.7 155.0
    984.9 1288
    mean 120.6 124.0 181.7 186.8 183.7 158.2 185.5 180.0 221.5
    SD 47.8171 46.92 45.392 40.089 44.284 36.342 48.046 65.676 67.524
    time [hours] after the
    seventh administration
    subject 12 15 24 36 AUC 0-38 Cmax Tmax Cmax/C24
    1 315.0 308.6 143.7 48.8 7198.9 340.5 10 2.4
    2 177.7 181.7 110.8 32.9 4226.1 177.7 12 1.5
    3 226.4 174.8 131.0 41.3 4997.6 226.4 12 1.7
    4 152.0 131.2 84.6 23.2 3509.2 170.4 1 2.0
    5 322.3 287.3 181.4 37.6 7121.6 358.4 10 2.2
    6 198.0 209.3 147.0 45.9 5437.7 209.3 15 1.4
    7 309.7 281.7 190.3 78.3 7213.0 309.7 12 1.5
    8 163.7 183.2 113.3 38.0 4331.6 163.7 12 1.4
    mean 232.8 211.9 135.3 43.2 5504.5 244.3 10.5 1.8
    SD 72.13 65.15 32.914 15.2362 1498.6 79.3 4.1 0.4
  • TABLE 4
    O-desmethyl tramadol levels multiple doses
    Figure US20130330404A1-20131212-P00899
    -desmethyl tramadol blood concentrations obtained after 7 consecutive
    administrations of 200 mg of tramadol HCl from example 5 to 8 healthy volunteers
    time [hours] after the seventh administration
    subject −24 0 1 1.5 2 4 6 8 10
    1 53.8 36.1 54.3 50.3 44.8 44.1 38.4 46.1 53.9
    2 98.1 38.5 43.9 43.4 41.6 34.9 30.6 32.9 39.0
    3 71.9 38.6 49.8 65.0 58.5 52.9 70.9 69.0 117.1
    4 28.0 32.4 54.8 40.5 49.5 47.1 41.3 40.8 47.2
    5 10.1 11.0 14.5 14.4 14.5 13.8 16.7 18.7 22.8
    6 9.2 8.4 11.4 10.8 10.0 9.1 7.9 7.5 7.5
    7 30.9 84.1 39.6 58.9 68.2 72.2 52.5 79.0 74.3
    8 34.2 33.7 41.5 42.0 43.9 41.5 38.6 40.8 43.2
    mean 40.7 32.5 38.7 40.4 41.1 39.4 37.1 41.8 50.6
    SD 26.3685 17.333 16.548 19.056 19.8 20.499 19.896 23.744 33.422
    time [hours] after the
    seventh administration
    subject 12 15.2 24 36 AUC 0-38 Cmax Tmax Cmax/C24
    1 58.4 43.8 29.4 10.4 1279.3 56.4 10 1.9
    2 45.8 55.0 40.0 17.4 1359.5 55.0 15 1.4
    3 72.6 84.5 90.4 21.6 2808.7 117.1 10 1.3
    4 49.5 53.6 31.2 12.8 1341.7 54.6 1 1.7
    5 23.8 23.6 15.3 4.2 583.2 23.8 12 1.6
    6 9.5 11.5 9.2 2.7 300.5 11.5 15 1.2
    7 86.6 78.4 54.8 34.8 2207.8 88.5 12 1.6
    8 44.0 42.3 33.8 13.8 1252.8 44.6 12 1.3
    mean 48.9 50.3 38.1 14.7 1387.6 56.4 10.9 1.5
    SD 25.06 28.98 26.269 19.2549 757.5 33.7 4.4 0.2
    Figure US20130330404A1-20131212-P00899
    indicates data missing or illegible when filed
    • EXAMPLE 6 Coated Beads
  • 30 kg of beads from Example 1 were coated first with 5.5 kg of the precoating suspension of Example 2 followed by 36 kg of the sustained release coating of Example 2.
    • EXAMPLE 7 30 mg Tablets
  • Tramadol Hcl 6.00 kg
    Lactose 0.72 kg
    Microcrystalline Cellulose 1.20 kg
    Povidone 0.18 kg
    Starch 0.56 kg
    Sodium Starch Glycolate 0.24 kg
    Magnesium Stearate 0.09 kg
    Purified Water 1.00 kg
  • Tablets containing 30 mg Tramadol were prepared as per method described in Example 3—using a 160 L planetary blend. The tablets weight was 75 mg.
    • EXAMPLE 8 200 mg Capsules
  • Hard gelatin capsules Size #0 were filled with one tablet of Example 7 and 341 mg of beads from Example 6 treated with 0.5% of Talc.
  • A dissolution test was performed on this drug composition using USP apparatus 12 at 100 rpm in 900 mL of water at 37° C.
  • Time Tramadol Percent
    [h] Dissolved
    1 28
    7 50
    24 100
    • EXAMPLE 9 300 mg Capsules
  • Hard gelatin capsules Size #00 were filled with one tablet of Example 7 and 568 mg of beads from Example 6 treated with 0.5% of Talc.
  • A dissolution test was performed on this drug composition using the same equipment and parameters as for Example 8.
  • Time Tramadol Percent
    [h] Dissolved
    1 21
    8 48
    24 95
  • As shown by the dissolution results of pharmaceutical preparations of examples 8 and 9, the Tramadol release profile is diphasic.
  • A Single Dose pharmaceutical study was undertaken with formulations of Examples 8 and 9.
  • Single Tramadol ER capsules containing 200 mg and 300 mg were administered in cross over to twenty healthy subjects without food. Blood was monitor and plasma analyzed for Tramadol content up to 72 hours.
  • Results are summarized in Table 5.
  • TABLE 5
    Tramadol and o-desmethyl-tramadol plasma concentration after single
    dose administered to 20 healthy volunteers of 200 mg (Example 8)
    and 300 mg (Example 9) of Tramadol formulation.
    O-demethyl-
    Tramadol Tramadol
    Plasma Level Plasma Level
    Time [mg/ml] [mg/ml]
    [h] 200 mg 300 mg 200 mg 300 mg
     0 0.0 0.0 0.0 0.0
      0.5 19.20 20.4 5.5 6.5
     1 123.7 121.6 23.2 24.2
      1.5 158.9 156.7 32.0 32.3
     2 168.1 159.9 35.5 35.1
      2.5 165.0 160.6 37.2 36.2
     3 152.3 156.1 35.0 36.8
      3.5 147.9 150.0 35.7 36.3
     4 144.5 152.2 35.3 38.2
     5 160.7 180.9 38.7 43.2
     6 175.2 228.0 39.9 50.1
     8 228.1 320.8 51.8 69.6
    10 271.6 385.8 62.4 86.4
    11 275.6 384.3 64.1 89.7
    12 273.9 387.8 64.7 89.7
    13 267.2 386.3 64.9 93.1
    14 255.7 384.9 63.4 95.0
    15 251.1 364.0 64.9 90.8
    16 232.0 344.0 61.7 88.8
    17 216.7 318.0 59.8 83.9
    18 198.7 302.2 56.1 81.4
    20 177.4 269.7 52.6 73.1
    24 126.9 201.0 40.2 57.5
    36 46.6 78.6 15.8 24.5
    48 18.5 33.0 6.4 10.6
    72 2.6 4.4 0.8 1.5
    Ratio Cmax/C24 2.2 1.9 1.6 1.7
    Tmax[h] 11 12 13-15 14

Claims (20)

What is claimed is:
1. An oral tramadol pharmaceutical composition for once daily administration, comprising an effective amount of tramadol or a pharmaceutically-acceptable salt thereof, providing in vivo, a time of tramadol peak plasma concentration (Tmax) greater than 10 hours and a peak tramadol plasma concentration (Cmax) which is less than three times a plasma concentration obtained 24 hours after administration (C24h) of a single dose of the composition.
2. The composition of claim 1, wherein the composition provides after repeated once daily administration in vivo, a time of tramadol peak plasma concentration (Tmax) greater than 10 hours, and a peak tramadol plasma concentration (Cmax) which is not more than three times the plasma concentration obtained 24 hours after administration.
3. The composition of claim 1, wherein said composition provides, after single administration in vivo, o-demethyl tramadol peak plasma concentration (Cmax) which is not more than twice the plasma concentration obtained 24 hours after administration (C24h).
4. The composition of claim 1, wherein said composition provides, after repeated daily administrations, o-demethyl tramadol peak plasma concentration (Cmax) which is not more than twice the plasma concentration obtained 24 hours after administration (C24h).
5. The composition of claim 1, wherein said composition provides, after single administration in vivo, a time of o-demethyl tramadol peak plasma concentration (Tmax) greater than 10 hours.
6. The composition of claim 1, wherein said composition provides, after repeated once daily administrations in vivo, a time of o-demethyl tramadol peak plasma concentrations (T max) greater than 10 hours.
7. The composition of claim 1, which exhibits an in vitro biphasic dissolution profile.
8. The composition of claim 1, which comprises individual tramadol-containing units which each release tramadol at a different rate.
9. The composition of claim 8, which comprises at least one individual unit from which about 80% of tramadol is released within about 6 hours.
10. The composition of claim 8, which comprises at least one individual unit from which about 80% of tramadol is released within 1 hour.
11. The composition of claim 1, which comprises sustained-release beads covered by layers containing tramadol from which the tramadol is released at a different rate than from the sustained-release beads.
12. The composition of claim 11, which comprises layers containing tramadol from which at least 80% of tramadol is released within about 6 hours.
13. The composition of claim 11, which comprises layers containing tramadol from which at least 80% of tramadol is released within about 1 hour.
14. The composition of claim 1, wherein a rapid rise in tramadol plasma concentration occurs in vivo within about 0.5 to 3 hours after administration.
15. The composition of claim 14, wherein a peak plasma concentration (Tmax) from said rapid rise in tramadol plasma concentration is less than the peak concentration (Cmax) measured between successive administration.
16. The composition of claim 1, which comprises multiple tramadol-containing units contained in a capsule.
17. The composition of claim 1, which comprises multiple tramadol-containing units compressed in a tablet.
18. The composition of claim 1, which exhibits a biphasic absorption profile in vivo under both fed and fasted administration conditions.
19. The composition of claim 1, which comprises a fast release tablet containing tramadol, and slow release beads containing tramadol, wherein a Cmax obtained from the fast release tablet is less than a Cmax from the slow release beads.
20. A method of managing post-surgery pain control, which comprises a step of administering the composition of claim 1, to a patient in need thereof, wherein said administering is once daily and effective under both fed and fasted conditions.
US13/506,390 2002-04-11 2012-04-17 Extended release composition containing tramadol Abandoned US20130330404A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/506,390 US20130330404A1 (en) 2002-04-11 2012-04-17 Extended release composition containing tramadol

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/119,939 US7858118B2 (en) 2001-04-11 2002-04-11 Extended release composition containing Tramadol
US12/926,463 US20110189269A1 (en) 2001-04-11 2010-11-18 Extended release composition containing tramadol
US13/506,390 US20130330404A1 (en) 2002-04-11 2012-04-17 Extended release composition containing tramadol

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/119,939 Continuation US7858118B2 (en) 2001-04-11 2002-04-11 Extended release composition containing Tramadol

Publications (1)

Publication Number Publication Date
US20130330404A1 true US20130330404A1 (en) 2013-12-12

Family

ID=33550841

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/119,939 Expired - Lifetime US7858118B2 (en) 2001-04-11 2002-04-11 Extended release composition containing Tramadol
US11/600,201 Abandoned US20070122478A1 (en) 2001-04-11 2006-11-16 Extended release composition containing tramadol
US12/926,463 Abandoned US20110189269A1 (en) 2001-04-11 2010-11-18 Extended release composition containing tramadol
US13/506,390 Abandoned US20130330404A1 (en) 2002-04-11 2012-04-17 Extended release composition containing tramadol

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US10/119,939 Expired - Lifetime US7858118B2 (en) 2001-04-11 2002-04-11 Extended release composition containing Tramadol
US11/600,201 Abandoned US20070122478A1 (en) 2001-04-11 2006-11-16 Extended release composition containing tramadol
US12/926,463 Abandoned US20110189269A1 (en) 2001-04-11 2010-11-18 Extended release composition containing tramadol

Country Status (4)

Country Link
US (4) US7858118B2 (en)
AU (1) AU2002337967A1 (en)
CA (1) CA2495463C (en)
WO (1) WO2004110410A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103948800A (en) * 2014-04-28 2014-07-30 彭英华 Capsule for preventing chill after anesthesia and preparation method thereof

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050182056A9 (en) * 2002-02-21 2005-08-18 Seth Pawan Modified release formulations of at least one form of tramadol
ES2377729T3 (en) * 2002-02-21 2012-03-30 Valeant International (Barbados) Srl Modified release formulations of at least one form of tramadol
US8323692B2 (en) * 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050084531A1 (en) * 2003-10-16 2005-04-21 Jatin Desai Tablet with aqueous-based sustained release coating
BRPI0612802A2 (en) * 2005-07-07 2010-11-30 Farnam Co Inc sustained release pharmaceutical compositions for extremely water soluble drugs
EP1940467B1 (en) * 2005-09-09 2016-11-02 Paladin Labs Inc. Sustained drug release composition
US7829120B2 (en) * 2005-09-09 2010-11-09 Labopharm Inc. Trazodone composition for once a day administration
JP2009543791A (en) * 2006-07-12 2009-12-10 ザ・ユニヴァーシティ・オブ・カンザス Multiparticulate formulations having immediate release and sustained release forms of tramadol
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
KR101366365B1 (en) * 2010-05-04 2014-02-21 주식회사 삼양바이오팜 Release controlled pharmaceutical composition comprising tramadol or pharmaceutically acceptable salts thereof, and oral dosage form comprising the composition
US20120009261A1 (en) 2010-07-06 2012-01-12 Grünenthal GmbH Novel gastro-retentive dosage forms
WO2012142273A1 (en) 2011-04-12 2012-10-18 Revogenex Inc. Intravenous administration of tramadol
US9980900B2 (en) 2015-12-22 2018-05-29 Revogenex Ireland Ltd Intravenous administration of tramadol
US9693949B1 (en) 2015-12-22 2017-07-04 Revogenex Ireland Ltd Intravenous administration of tramadol
US10022321B2 (en) 2016-06-30 2018-07-17 Revogenex Ireland Ltd. Intravenous administration of tramadol
CN111751470B (en) * 2020-07-07 2023-05-05 多多药业有限公司 Detection control method for new impurities in tramadol hydrochloride preparation
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288505A (en) * 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
IL119660A (en) * 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6156342A (en) * 1998-05-26 2000-12-05 Andex Pharmaceuticals, Inc. Controlled release oral dosage form
US6806294B2 (en) * 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
CN100563656C (en) * 2000-02-08 2009-12-02 欧罗赛铁克股份有限公司 Anti-destructive oral opioid agonists
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103948800A (en) * 2014-04-28 2014-07-30 彭英华 Capsule for preventing chill after anesthesia and preparation method thereof

Also Published As

Publication number Publication date
AU2002337967A1 (en) 2005-01-04
US20030143270A1 (en) 2003-07-31
WO2004110410A1 (en) 2004-12-23
CA2495463C (en) 2011-06-14
US20110189269A1 (en) 2011-08-04
US7858118B2 (en) 2010-12-28
US20070122478A1 (en) 2007-05-31
CA2495463A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
US20130330404A1 (en) Extended release composition containing tramadol
US6077533A (en) Powder-layered oral dosage forms
CA2348090C (en) Oral pulsed dose drug delivery system
US5670172A (en) Pharmaceutical spheroid formulation
JP5845172B2 (en) Orally disintegrating tablet composition comprising a combination of high and low dose drugs
RU2428176C2 (en) Systems of medication delivery, containing weak-base medications and organic acids
EP0711152B1 (en) Powder-layered oral dosage forms
CN1886119B (en) Pantoprazole multiparticulate formulations
US20110212171A1 (en) Taste masked topiramate composition and an orally disintegrating tablet comprising the same
AU2002253039B2 (en) Tramadol-based medicament
KR101380507B1 (en) Solid oral form with dual release profile, containing multiparticulates
SG184388A1 (en) Pharmaceutical formulations for the treatment of overactive bladder
US9034902B2 (en) Methods for treatment of attention deficit hyperactivity disorder
US7063864B1 (en) Morphine sulphate microgranules, method for preparing same and compositions containing same
US20070281019A1 (en) Phenylephrine pulsed release formulations and pharmaceutical compositions
US7060293B1 (en) Powder-layered oral dosage forms
EP1190712B1 (en) Oral once daily tramadol beads composition
ES2860694T3 (en) Sustained-release pharmaceutical composition containing rivastigmine
KR20060065319A (en) Sustained-release pellets containing venlafaxine hydrochloride
MX2008004282A (en) Pharmaceutical dosage forms having immediate release and/orcontrolled release properties
AU2013200211A1 (en) Pharmaceutical formulations for the treatment of overactive bladder

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION